Finance

Lists
LENZ:NASDAQ
Lenz Therapeutics Inc
3,84 USD
-0,39%
(-0,015) 1D
30-сен., 12:49:15 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LENZ...
Open
3,90 USD
High
3,90 USD
Low
3,75 USD
Mkt. cap
120,81 млн
Avg. vol.
689,78 миң
Volume
322,80 миң
52-wk high
50,19 USD
52-wk low
3,60 USD
EPS
-4,08 USD
Beta
0,66
Shares outstanding
31,42 млн
No. of employees
152
Open
3,90 USD
High
3,90 USD
Low
3,75 USD
Mkt. cap
120,81 млн
Avg. vol.
689,78 миң
Volume
322,80 миң
52-wk high
50,19 USD
52-wk low
3,60 USD
EPS
-4,08 USD
Beta
0,66
Shares outstanding
31,42 млн
No. of employees
152
About Lenz Therapeutics Inc
CEO-
Employees152
Founded2013
HeadquartersСолана Бич, Калифорния, Америка Кошмо Штаттары
SectorPharmaceutical industry
Websitelenz-tx.com
Analyst ratings
Based on 6 analysts giving stock ratings to LENZ in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for LENZ in the last 3 months.
Highest
Current 3,84 USD
60,00 USD (+1 460,47%)
Average
24,40 USD (+534,59%)
Lowest
7,00 USD (+82,05%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Gerberry
Bank of America Securities
Hold
Downgraded
7,00 USD
+82,1%
08/12/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
08/12/2026
Biren Amin
Piper Sandler
Hold
Maintained
7,00 USD
+82,1%
08/12/2026
Yigal Nochomovitz
Citi
Buy
Maintained
10,00 USD
+160,1%
08/13/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
38,00 USD
+888,3%
08/12/2026
Stacy Ku
TD Cowen
Buy
Reiterated
60,00 USD
+1 460,5%
08/12/2026
Last report
2026-ж., 11-авг.
Fiscal period
Q2 2026
EPS / Est. (USD)
-1,02 USD / -1,07 USD
+5,10%beat
Revenue / Est. (USD)
5,49 млн / 2,38 млн
+130,76%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
12,50 млн
1,59 млн
1,90 млн
5,49 млн
Cost of goods sold
-
418,00 миң
1,08 млн
280,00 миң
Cost of revenue
-
418,00 миң
1,08 млн
280,00 миң
Research and development expenses
3,79 млн
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27,60 млн
39,63 млн
44,96 млн
39,38 млн
Operating expense
31,39 млн
39,63 млн
44,96 млн
39,38 млн
Total operating expenses
31,39 млн
40,05 млн
46,04 млн
39,66 млн
Operating income
-18,89 млн
-38,46 млн
-44,14 млн
-34,17 млн
Other non operating income
-14,00 миң
-417,00 миң
3,00 миң
-13,00 миң
EBT including unusual items
-16,70 млн
-35,89 млн
-41,49 млн
-31,92 млн
EBT excluding unusual items
-16,70 млн
-35,89 млн
-41,49 млн
-31,92 млн
Income tax expense
-
2,00 миң
-
3,00 миң
Effective tax rate
-
-0,01%
-
-0,01%
Other operating expenses
-
-
-
-
Net income
-16,70 млн
-35,90 млн
-41,49 млн
-31,92 млн
Net profit margin
-133,60%
-2 260,45%
-2 182,43%
-581,81%
Earnings per share
-0,59
-1,16
-1,32
-1,02
Interest and investment income
2,20 млн
2,99 млн
2,64 млн
2,27 млн
Interest expense
-
-
-
-
Net interest expenses
2,20 млн
2,99 млн
2,64 млн
2,27 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-18,76 млн
-38,36 млн
-44,02 млн
-34,06 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору